Anne Larochelle, MD
Endocrinology, Diabetes & Metabolism · Myrtle Beach, SCNPI 1760485320
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 26.7% of the total. Reporting peaked in 2023 at $11,346 and has fallen 93.3% since, to $766 in 2025.
Across 722 payments — averaging $44.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$9K
- Novo Nordisk$7K
- Amgen$6K
- Johnson & Johnson$1K
- UCB, Inc.$1K
- AstraZeneca$933
- plus $8K from 52 others
Across 21 payments — averaging $30,781 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$646K
What the payments were for
- Consulting fees$10,13332%
- Speaking & faculty fees$1,4004%
- Travel & lodging$2,2687%
- Food & beverage$17,78856%
- Education$2781%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$8,039
- Victoza$4,866
- TEPEZZA$1,730
- EVENITY$373
- MOUNJARO$356
- SAPHNELO$345
- MINIMED 770G$291
- Prolia$251
- Tymlos$234
- ORENCIA$231
- BENLYSTA$219
- MINIMED 780G$201
- DEXCOM G7 GSS (161)$167
- InPen$156
- Qutenza$128
- AREXVY$127
- Kerendia$125
- Vascepa$125
- FreeStyle Libre 2$125
- Ozempic$123
How this compares
$31,926 in reported general payments places this provider in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 227 | $419,619 |
| Tresiba Flextouch U-200Insulin Degludec | 103 | $177,243 |
| FarxigaDapagliflozin Propanediol | 54 | $82,681 |
| MounjaroTirzepatide | 60 | $73,520 |
| JardianceEmpagliflozin | 49 | $66,062 |
| TrulicityDulaglutide | 33 | $46,660 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $44,030 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $43,350 |
| GlyxambiEmpagliflozin/Linagliptin | 24 | $39,812 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 15 | $37,510 |
| SynthroidLevothyroxine Sodium | 306 | $35,411 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 19 | $34,373 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $26,963 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $24,798 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $23,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $6,504 | $453,991246 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $84 | $149,22599 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $855 | $125,941119 claims |
| AstraZenecaFarxiga | $933 | $82,68154 claims |
| AmgenEvenity (2 Syringes) | $5,569 | $37,51015 claims |
| AbbVieSynthroid | $579 | $35,411306 claims |
| MerckJanuvia | $194 | $19,52317 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $8,522 | $15,25013 claims |
| PfizerLevoxyl | $14 | $1,87631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Myrtle Beach
- Gauri DhirMyrtle Beach$417K
- Donald EagertonMyrtle Beach$284K
- Jocelyn MyersMyrtle Beach$26K
- Alimitha KodaliMyrtle Beach$5K
- Zhiwei ZhangMyrtle Beach$3K
- Paul BunnMyrtle Beach$3K
- Matthew CrabtreeMyrtle Beach$2K
- Sahana ParthasarathyMyrtle Beach$2K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.